Skip to NavigationSkip to content

Biopharma firm F-star appoints Dr Neil Brewis as CSO

Published on: 02/11/15

F-star, a biopharma company focused on immuno-oncology, has hired Dr Neil Brewis as chief scientific officer. 

Dr Brewis is a former vice president and head of biopharmaceutical research at GlaxoSmithKline. In this role he led a global team of 300 scientists working on numerous monoclonal antibodies, antibody fragments, and protein therapeutics from target validation into early clinical development.  

He has 20 years’ experience in drug discovery and development and prior to joining GSK, he played a key leadership role, as head of research at Domantis until the company was acquired by GSK in 2007. He has a PhD in biochemistry from Dundee University and was awarded an honorary doctor of science from Hertfordshire University in 2014.

Commenting on the appointment, John Haurum, chief executive of F-star, says: “We are very pleased to welcome Neil to our team. His significant track record and expertise in applying antibody technologies to discover and develop clinical products will further enable us to move our portfolio of immuno-oncology compounds into the clinic."

Brewis adds: “F-star is an emerging world leader in bispecific antibody drug discovery and I am delighted to join the company at this exciting time to help maximise the potential of the technology and progress compounds into clinical development.”

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches